Insulet Raises Repurchase Authorization $350M, Forecasts 20%-22% 2026 Sales Growth
Insulet posted Q4 adjusted EPS of $1.55, surpassing the $1.45 consensus, with sales of $783.8 million up 31.2% year-over-year and gross margin rising to 72.5%. The board approved a $350 million buyback increase, and management forecast 2026 sales of $3.25 billion–$3.304 billion, up 20%–22%, with EPS growth over 25%.
1. Q4 Earnings and Margins
Insulet reported adjusted earnings of $1.55 per share in Q4, beating the $1.45 estimate, on sales of $783.8 million, up 31.2% year-over-year (29% in constant currency). Gross margin improved by 40 basis points to 72.5%, while adjusted operating margin rose 30 basis points to 18.7%.
2. Share Buyback Plan
The board approved a $350 million increase to the share repurchase authorization, with approximately $300 million earmarked for repurchases in Q1 2026. Management cited a strong balance sheet and cash flow to fund the program without tapping new debt.
3. 2026 Outlook
Insulet forecast fiscal 2026 sales of $3.25 billion to $3.304 billion, representing 20%–22% growth, including 21%–23% Omnipod products expansion. Adjusted operating margin is expected to expand by about 100 basis points, and adjusted EPS is projected to grow by over 25%.